Lantern Pharma shareholders elect all six directors, approve option repricing, ratify auditor at 2025 annual meeting

Lantern Pharma Inc.

All six director nominees elected: Keyser (2.21M for), Sharma (2.21M), Chandru (2.20M), Maccecchini (2.21M), Schalop (2.21M), Silberstein (2.21M); broker non-votes 5.19M.
One-time repricing of stock options under 2018 Equity Incentive Plan approved: 1.46M for, 759K against, 30K abstain, 5.19M broker non-votes.
Ratification of EisnerAmper LLP as auditor for FY2025 passed: 7.37M for, 44K against, 26K abstain; no broker non-votes on this item.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.